SPEECH-PROCESSING
10.4.2024 09:03:28 CEST | Business Wire | Press release
Philips Dictation by Speech Processing Solutions, a globally leading innovator in voice technology, has announced the latest innovation in their professional cloud-based dictation and transcription solution, Philips SpeechLive. The enhancement integrates speech recognition from Nuance Dragon. This major development offers the most accurate dictation workflow, leading to new levels of efficiency for legal professionals worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410464123/en/
Philips SpeechLive with Nuance Dragon (Graphic: Business Wire)
Featuring highly precise AI-powered speech recognition integrated directly into legal workflows, this latest version of SpeechLive continuously learns for unmatched accuracy. It empowers time-constrained lawyers to create high-quality documentation while enhancing efficiency and expediting documentation completion. Additionally, assistants can access automated transcripts together with the original recordings for quick corrections, freeing them to concentrate on more meaningful tasks, ultimately boosting work satisfaction and productivity.
Dr. Thomas Brauner, CEO of Speech Processing Solutions, emphasized the significance of this partnership, stating, "The integration of Nuance Dragon into Philips SpeechLive marks a significant enhancement for legal professionals. By merging top-tier AI-powered speech recognition with the best-in-class dictation platform, we're empowering legal professionals to benefit from the best of both worlds. This unique combination will streamline their workflow and achieve new levels of efficiency and accuracy in their document creation process."
Key benefits for legal professionals include:
- Specialized Legal Vocabularies: Access tailored legal vocabularies for precise transcription and industry-specific terminology adherence.
- Custom Profiles: Personalize speech profiles to streamline workflows and boost efficiency, eliminating repetitive corrections.
- Personalized User Recognition: Nuance Dragon's adaptive learning optimizes transcription accuracy, tailoring to individual preferences.
- Enhanced Functionality: Experience streamlined features within SpeechLive, including live dictation and recording capabilities, enhancing workflow efficiency.
- Enhanced Mobility: Access SpeechLive across devices for flexible work arrangements, including PCs and mobile phones, facilitating work from any location.
- Real-time speech recognition with Dragon Bar: Dictate directly into applications for convenience, such as Word documents or Client Management Systems (CMS), simplifying the documentation process.
- Data Security: Philips SpeechLive prioritizes data security, with servers located in five regions worldwide and features such as Multifactor Authentication and Single Sign-on.
In the legal profession, effective communication requires reliance on and integration of precise speech recognition and a seamlessly integrated workflow system.
Philips SpeechLive platform's versatility and convenience cater to the dynamic needs of legal professionals. This all-in-one dictation and transcription platform empowers time-pressed professionals and high-demand firms to save time and earn more money by automating the documentation process between authors and transcriptionists, also allowing them to work flexibly from anywhere.
Free demos of Philips SpeechLive with Nuance Dragon integration are available at www.speechlive.com/dragon-speech-recognition.
About Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.
Follow Us:
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410464123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom